RBC Comments on Amgen (AMGN) Repatha Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
March 15, 2015 11:15 AM EDTSanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (TM) (alirocumab) Published in The New England Journal of Medicine
- Robust and consistent LDL-C lowering demonstrated with PraluentTM in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date - Â - Fewer major cardiovascular events observed with PraluentTM in post hoc analysis -
PARIS and TARRYTOWN, N.Y., March 15, 2015... More
Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine
March 15, 2015 11:00 AM EDTTHOUSAND OAKS, Calif., March 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha (evolocumab), a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. These data were presented today at a Late-Breaking Clinical Trial session at the American College of Cardiology's 64th Annual Scientific Session (ACC.15) and published in the New England Journal of Medicine. A two-year analysis of Repatha safety and tolerability data from the longest proprotein convertase... More
